pSivida Corp (NASDAQ:PSDV; ASX:PVA) has signed two funded technology evaluation agreements with a leading global pharmaceutical company.
The agreements will each evaluate the use of pSivida’s Durasert™ technology to deliver a specific compound to treat a significant ophthalmic disease.
pSivida's strategy includes partnering product development with market leaders in appropriate circumstances, allowing expansion beyond its own product development.
pSivida Corp is a leader in the development of sustained release, drug delivery products for treating eye diseases.
pSivida developed three of the four back of the eye implants approved by the FDA - Vitrasert and Retisert, licensed to Bausch & Lomb; and ILUVIEN, licensed to Alimera Sciences.
pSivida’s lead product candidate, Medidur™ for the treatment of posterior uveitis, is currently in pivotal phase III clinical trials.
pSivida is also involved in the development of products focused on ocular and systemic delivery of biologics and drugs to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases.
These products are in preclinical development utilizing pSivida’s two core technology platforms in Durasert and/or Tethadur.
Add to My Watchlist
What is My Watchlist?